Dostarlimab vs Retifanlimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Dostarlimab
Marketed by GlaxoSmithKline and partners
NCT04655976 · Phase 2/3 · active, not recruiting
Patients were randomly assigned to three arms (758 enrolled) with docetaxel as the active comparator, but the study was open label, with no masking. The primary endpoint, overall survival, was not significantly improved by dostarlimab plus docetaxel (HR 0.96, 95% CI 0.77 to 1.20, p=0.37) or by the triplet with cobolimab (HR 0.85, 95% CI 0.68 to 1.06, p=0.08), so the primary comparisons were not met.
Next expected readout: January 2027 · NCT06879717 (registry estimate)
Reported efficacy
Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks); Overall Survival (OS) (Arm B Versus Arm C) (Up to approximately 234 weeks): Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 Months (95% CI 10.6 to 14.2) vs Docetaxel (Arm C) 11.3 Months (95% CI 9.5 to 13.9) (missed)
Result source: NCT04655976
Retifanlimab
Marketed by Incyte
NCT04205812 · Phase 3 · completed
Participants were randomly assigned and double-blinded to receive retifanlimab or placebo with standard chemotherapy, with 391 in the retifanlimab group and 192 in the control group. The hard clinical primary endpoint of overall survival was met, favoring retifanlimab (hazard ratio 0.75; p=0.0042).
Next expected readout: December 2027 · NCT07219576 (registry estimate)
Reported efficacy
Overall Survival (up to 39.1 months): Overall Survival (up to 39.1 months): Retifanlimab + Chemotherapy 18.1 months (95% CI 16.2 to 21) vs Placebo + Chemotherapy 13.4 months (95% CI 11 to 16.7) (met)
Result source: NCT04205812
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Dostarlimab | Retifanlimab |
|---|---|---|
| PFS, median | 4.4 vs 4.1vs DocetaxelNCT046559762 other results
| 7.7 vs 5.5+2.2 vs placeboNCT04205812 |
| OS, median | 11.9 vs 11.3vs DocetaxelNCT046559763 other results
| 18.1 vs 13.4+4.7 vs placeboNCT04205812 |
| ORR | 18.7% vs 14.5%vs DocetaxelNCT046559762 other results
| 51.7% vs 38.5%+13.2 vs placeboNCT04205812 |
| Duration of response, median | 8.3 vs 8.8vs DocetaxelNCT046559762 other results
| 12.7 vs 6.1+6.6 vs placeboNCT04205812 |
PFS, median
- Dostarlimab
- 4.4 vs 4.1vs DocetaxelNCT04655976
2 other results
- 4.2 vs 4.1 NCT04655976
- 4.4 NCT03308942
- Retifanlimab
- 7.7 vs 5.5+2.2 vs placeboNCT04205812
OS, median
- Dostarlimab
- 11.9 vs 11.3vs DocetaxelNCT04655976
3 other results
- 11.8 vs 11.3 NCT04655976
- 11.9 NCT04655976
- 11.8 NCT04655976
- Retifanlimab
- 18.1 vs 13.4+4.7 vs placeboNCT04205812
ORR
- Dostarlimab
- 18.7% vs 14.5%vs DocetaxelNCT04655976
2 other results
- 18.3% vs 14.5% NCT04655976
- 9.1% NCT03308942
- Retifanlimab
- 51.7% vs 38.5%+13.2 vs placeboNCT04205812
Duration of response, median
- Dostarlimab
- 8.3 vs 8.8vs DocetaxelNCT04655976
2 other results
- 7.1 vs 8.8 NCT04655976
- 21.5 NCT03308942
- Retifanlimab
- 12.7 vs 6.1+6.6 vs placeboNCT04205812
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Dostarlimab: 3 of 4 rows · Retifanlimab: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Dostarlimab | Retifanlimab |
|---|---|---|
| Dropout rate | 25.6%Cobolimab + Dostarlimab + Docetaxea NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 show 3 more results21.6%Dostarlimab + Docetaxel (Arm B) NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 —Stage 2 (Cohort 1A): Niraparib + T NCT03308942 · Phase 2 · registry result, not featured evidence · combination —Stage 2 (Cohort 2A): Niraparib + T NCT03308942 · Phase 2 · registry result, not featured evidence · combination | 100%Retifanlimab + Chemotherapy NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 1 more result—Retifanlimab Monotherapy NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 |
| Discontinued due to AEs | —Cobolimab + Dostarlimab + Docetaxea NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 show 3 more results—Dostarlimab + Docetaxel (Arm B) NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 —Stage 2 (Cohort 1A): Niraparib + T NCT03308942 · Phase 2 · registry result, not featured evidence · combination —Stage 2 (Cohort 2A): Niraparib + T NCT03308942 · Phase 2 · registry result, not featured evidence · combination | —Retifanlimab + Chemotherapy NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 1 more result—Retifanlimab Monotherapy NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 |
| Serious AEs | 33.8%Cobolimab + Dostarlimab + Docetaxea NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 show 3 more results42.7%Dostarlimab + Docetaxel (Arm B) NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 58.3%Stage 2 (Cohort 1A): Niraparib + T NCT03308942 · Phase 2 · registry result, not featured evidence · combination —Stage 2 (Cohort 2A): Niraparib + T NCT03308942 · Phase 2 · registry result, not featured evidence · combination | 40.6%Retifanlimab + Chemotherapy NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 1 more result20.3%Retifanlimab Monotherapy NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 |
| Most frequent reported AEs | a anaemia 34.8% neutropenia 31.5% fatigue 29.5% NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 show 2 more resultsanaemia 31.5% fatigue 29.8% diarrhoea 29.5% NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3 nausea 58.3% diarrhoea 50% fatigue 41.7% NCT03308942 · Phase 2 · registry result, not featured evidence · combination | anaemia 60.4% (placebo 56.8%) decreased appetite 22.6% (placebo 13.2%) neutrophil count decreased 21.6% (placebo 17.4%) NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 1 more resultaspartate aminotransferase increased 23.7% (placebo 22.1%) anaemia 22% (placebo 56.8%) alanine aminotransferase increased 15.3% (placebo 23.7%) NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 |
Notes
- aPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Dostarlimab
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dostarlimab's landscape · Retifanlimab's landscape